Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Malem, H. Barker, N. Shafi, D. Wat, C. Haworth, R. A. Floto (Cambridge, United Kingdom). Rates of ophthalmic complications due to ethambutol in patients with non-tuberculous mycobacteria. Eur Respir J 2012; 40: Suppl. 56, 4375

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of intravenous isoniazid and ethambutol administration in patients with new smear positive drug-susceptible pulmonary tuberculosis with tuberculous meningoencephalitis and HIV co-infection in the intensive phase of treatment Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019 Direct molecular testing for isoniazid and rifampicin resistance from respiratory specimens of patients with tuberculosis Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013 Respiratory infections associated with nontuberculous mycobacteria in non-HIV patients Source: Eur Respir J 2006; 28: 1211-1215 Year: 2006 The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease Source: Eur Respir J 2015; 45: 1177-1179 Year: 2015 Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Screening non-tuberculous mycobacteria in patients with bronchiectasis Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection Year: 2019 Cure rates in nontuberculous mycobacterial pulmonary disease Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019 The management of non-tuberculous mycobacteria Source: International Congress 2016 – New therapies for chronic respiratory infections Year: 2016 Efficacy and safety of linezolid for the treatment of multidrug resistant tuberculosis (MDR-TB) and disease by non tuberculous mycobacteria (NTM) Source: Annual Congress 2011 - Treatment of tuberculosis and adverse drug reactions Year: 2011 Cardiovascular disease risk in patients with nontuberculous mycobacteria disease treated with macrolide Source: International Congress 2017 – Clinical update on bronchiectasis and nontuberculous mycobacteria (NTM) infections Year: 2017 Management of pulmonary nontuberculous mycobacteria disease Source: Eur Respir Monogr 2018; 81: 222-237 Year: 2018 Non tuberculous mycobacteria infections in patients with silicosis Source: Virtual Congress 2020 – Occupational lung diseases Year: 2020 Pulmonary diseases due to non-tuberculous mycobacteria in TB referral clinical center Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Safety of intravenous amikacin in the treatment of pulmonary non-tuberculous mycobacterial disease Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Nontuberculous mycobacteria infections in patients receiving immunosuppressive agents Source: Eur Respir Monogr 2018; 81: 238-253 Year: 2018 Surgery in nontuberculous mycobacteria pulmonary disease Source: Breathe, 14 (4) 288; 10.1183/20734735.027218 Year: 2018 A case of atypical pulmonary mycobacteriosis in an elderly patient caused by rifabutin resistant Mycobacterium celatum Source: International Congress 2019 – CCC Respiratory infections Year: 2019 Clinical analysisof patients with pulmonary nontuberculous mycobacterial disease complicated with pneumothorax Source: Annual Congress 2013 –Non-tuberculous mycobacteria: clinical management Year: 2013 Therapeutic drug monitoring of isoniazid, rifampin, and pyrazinamide in HIV-infected patients with tuberculosis Source: Annual Congress 2012 - Tuberculosis: clinical findings III Year: 2012 Nontuberculous mycobacteria in bronchiectasis: prevalence and patient characteristics Source: Eur Respir J 2006; 28: 1204-1210 Year: 2006